- Home
- MYGN
MYGN
Myriad Genetics Inc.
as 07-26-2024 4:00pm EST
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.2B | IPO Year: | 1995 |
| Target Price: | $25.00 | AVG Volume (30 days): | 820.4K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.82 - $28.90 | Next Earning Date: | 08-05-2024 |
| Revenue: | $774,200,000 | Revenue Growth: | 11.44% |
| Revenue Growth (this year): | 12.65% | Revenue Growth (next year): | 7.61% |
Stock Insider Trading Activity of Myriad Genetics Inc. (MYGN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SPIEGELMAN DANIEL K | MYGN | Director | Jun 3 '24 | Sell | $22.05 | 3,788 | $83,525.40 | 32,917 | SEC Form 4 |
| SPIEGELMAN DANIEL K | MYGN | Director | Jun 3 '24 | Sell | $22.04 | 3,788 | $83,487.52 | 36,705 | SEC Form 4 |
| DIAZ PAUL J | MYGN | President and CEO | May 13 '24 | Sell | $25.07 | 75,000 | $1,880,415.00 | 1,066,166 | SEC Form 4 |
| DIAZ PAUL J | MYGN | President and CEO | May 13 '24 | Sell | $25.21 | 95,000 | $2,394,798.00 | 1,141,166 | SEC Form 4 |
| DIAZ PAUL J | MYGN | President and CEO | May 13 '24 | Sell | $25.13 | 57,844 | $1,453,550.31 | 1,236,166 | SEC Form 4 |
| Newcomer Lee Nisley | MYGN | Director | May 13 '24 | Sell | $25.30 | 6,200 | $156,860.00 | 66,650 | SEC Form 4 |
| Riggsbee Richard Bryan | MYGN | Chief Financial Officer | Dec 1 '23 | Sell | $19.09 | 30,000 | $572,835.00 | 291,812 | SEC Form 4 |
Latest Myriad Genetics Inc. News
MYGN Breaking Stock News: Dive into MYGN Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
MYGN: What does Argus have to say about MYGN?
Zacks
8 days ago
INCY or MYGN: Which Is the Better Value Stock Right Now?
GlobeNewswire
10 days ago
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
Argus Research
10 days ago
MYGN: Raising target price to $22.00
Zacks
11 days ago
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
MT Newswires
15 days ago
Myriad Genetics, Personalis to Cross-License IP on Minimal Residual Disease Tests
GlobeNewswire
15 days ago
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Zacks
17 days ago
Myriad Genetics (MYGN) Advances in MRD Space With New Patent
Compare MYGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYGN Myriad Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.